Search

everythinglearnresearchcommunity

for

Search:↓

Blocking certain proteins can reduce skin inflammation caused by cancer treatment.

Baricitinib is a safe and effective treatment for severe alopecia areata.

Ebastine may promote hair regrowth by increasing cell growth through the ERK pathway.

RANK-RANKL signaling is essential for hair growth and skin health.

ATR12-351 ointment safely delivers LEKTI protein to the skin, reducing enzyme activity in Netherton syndrome.

Dual-targeted therapy is effective and safe for difficult-to-treat inflammatory bowel disease.

Imatinib mesylate can cause skin lightening, especially in Chinese patients, due to its effect on pigment production.

Janus kinase inhibitors may effectively treat severe alopecia areata unresponsive to other treatments.

Non-coding RNA boosts retinoic acid production and signaling, aiding regeneration.

Finasteride reduces prostate cancer risk but may increase high-grade tumors; new drugs and better diagnosis are in development, but funding and industry commitment are challenges.

ROR-alpha may increase the growth of certain breast cancer cells by boosting aromatase, which could affect breast cancer prognosis.

Most children with CNS tumors on targeted therapy had skin reactions, which were generally treatable without stopping the therapy.

Diphencyprone increases Bcl-2 protein in patients with hair regrowth from alopecia areata.

Patients and doctors often agree on the severity of eyebrow and eyelash hair loss in severe alopecia areata.

Researchers found three different ways drugs work to treat hair loss from alopecia areata and identified key factors for personalized treatment.

Tofacitinib helped regrow hair in most patients with severe hair loss.

The ABI1 gene contributes to prostate cancer progression and treatment resistance.

JAK inhibitors are effective for long-term management of alopecia areata.

RSPO1 mutations in certain patients lead to skin cells that don't develop properly and are more likely to become invasive, increasing the risk of skin cancer.

Imatinib can cause hair loss due to lichen planopilaris.

PROTACs show promise in cancer treatment by effectively degrading specific harmful proteins.

Daprodustat, combined with PAβN, could be a new antibacterial treatment.

Topical JAK inhibitors may help treat alopecia universalis by promoting hair regrowth.

JAK inhibitors like baricitinib are a new FDA-approved treatment for alopecia areata, but safety data is incomplete.

The PRP-like cosmetic with biomimetic peptides is potentially effective and safe for treating alopecia areata.

Ablative fractional laser treatment nearly matches the gene reduction effects of topical vismodegib in skin cancer.

Baricitinib is effective and safe for severe alopecia areata, working similarly with or without an atopic background.

PDRN helps repair tissue and improve wound healing with a high safety profile.